PCNA binding protein, preparation method and application

By developing recombinant binding proteins that can specifically bind PCNA, the problems of unstable serum sources and large batch differences in anti-PCNA antibody detection are solved, and efficient and stable PCNA antigen identification and diagnostic assistance are achieved.

CN118909110AActive Publication Date: 2024-11-08ZHUHAI LIVZON DIAGNOSTICS +1

Patent Information

Application Number
CN202411130894.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

In the existing anti-PCNA antibody detection kits, calibrated products and quality control products mainly use patient serum, which is difficult to obtain and unstable, resulting in large batch differences, making it difficult to achieve large-scale production and high-affinity testing.

Method used

A PCNA binding protein capable of specifically binding to PCNA is developed, expressed and purified by recombinant technology, for the identification and auxiliary diagnosis of PCNA antigens, as a standard product and a quality control product during detection.

Benefits of technology

It realizes efficient expression and purification of PCNA-binding proteins, simplifies the operation process, reduces batch differences, improves the stability and controllability of detection, and avoids the instability and high cost problems of serum sources.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909110A_ABST
    Figure CN118909110A_ABST
Patent Text Reader

Abstract

The invention provides a PCNA binding protein as well as a preparation method and application thereof, and relates to the technical field of biology. The PCNA binding protein contains a complementarity determining region of a heavy chain variable region and a complementarity determining region of a light chain variable region, wherein the complementarity determining region of the heavy chain variable region comprises amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region as shown in SEQ ID NO.1; the complementarity determining region of the light chain variable region comprises amino acid sequences which are consistent with the amino acid sequences of VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region as shown in SEQ ID NO.2. The binding protein has good specific binding capacity with PCNA, and can be used for identification of PCNA antibodies or PCNA antigens and auxiliary diagnosis and detection of PCNA antibody positive diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibodies, in particular to a PCNA binding protein, a preparation method and an application thereof. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Proliferating cell nuclear antigen (PCNA), also known as cyclin 2, was first discovered in the serum of SLE patients by Miyachi et al. using double diffusion immunoprecipitation technology in 1978. It is named because it exists in actively proliferating cells. The traditional PCNA protein, with a molecular weight of 34kDa, has been confirmed to be a co-protein or processing factor of DNA polymerase delta. It is highly conserved in eukaryotic cells. It is connected to each other by three monomers to form a homotrimeric ring structure. It can act as a sliding clamp around double-stranded DNA and play a role in DNA replication, chromatin remodeling, DNA damage repair, and cell cycle progression. PCNA protein is one of the core molecules that determine the life and death of cells. The regulatory mechanism of its expression is as follows: PCNA gene is induced by p53, and PCNA protein interacts with p53 regulatory proteins Gadd45, MyD118, CR6, and most importantly p21 in the process of determining cell fate. On the one hand, if PCNA protein is present in large amounts in the cell in the absence of p53, DNA replication occurs. On the other hand, if PCNA protein levels are high in the cell in the presence of p53, DNA repair occurs. If PCNA loses its function or is absent or present in small amounts in the cell, the cell undergoes apoptosis.

[0004] Anti-PCNA antibodies are specific antibodies for systemic lupus erythematosus and can be used as marker antibodies for systemic lupus erythematosus. If the test is positive, it is possible that the patient has systemic lupus erythematosus, but its positive rate is low. In recent years, studies have also confirmed that anti-PCNA antibodies are not unique to systemic lupus erythematosus and can appear in many other autoimmune diseases. Anti-PCNA antibodies can also be seen in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. In addition, anti-PCNA antibodies have been detected in patients with malignant tumors (such as small cell lung cancer).

[0005] At present, the calibrators and quality control materials in the anti-PCNA antibody detection kit are mainly patient serum. Since it is difficult to obtain positive serum, the source is unstable, and the performance of each serum is difficult to be stable, it is of great significance and value to develop anti-PCNA recombinant monoclonal antibodies that can be mass-produced, have small batch differences, and have high affinity for the development of clinical detection kits.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The object of the present invention is to provide a PCNA-binding protein, which has good specific binding ability with PCNA. Based on the PCNA-binding protein provided by the present invention, the present invention also aims to provide its application. Another object of the present invention is to develop a PCNA-binding protein with good binding activity in a simpler method for operation, which can be used for the identification of PCNA antigens, and assists in the diagnosis or auxiliary diagnosis of PCNA antibody-positive diseases.

[0008] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0009] Definition of terms:

[0010] In this article, PCNA refers to proliferating cell nuclear antigen (PCNA), also known as cyclin 2. With a molecular weight of 34 kDa, it is highly conserved in eukaryotic cells, with three monomers interconnected to form a homotrimeric ring structure. PCNA is closely related to cell DNA synthesis, plays an important role in the initiation of cell proliferation, and participates in many important cell events, such as cell DNA damage repair, cell cycle regulation, chromosome recombination, DNA methylation, and cell apoptosis.

[0011] The PCNA binding protein provided by the present invention can specifically bind to PCNA, and the PCNA bound by the PCNA binding protein includes PCNA naturally expressed by cells or PCNA expressed by cells transfected with PCNA genes. The PCNA bound by the PCNA binding protein also includes artificially modified PCNA, and the artificial modification includes but is not limited to mutation, truncation or polypeptide or protein fused with other domains, and retains the necessary antigenic epitope for binding to the antibody.

[0012] The technical term "binding protein" herein refers to a protein that binds to a specific antigen, and generally refers to all proteins and protein fragments that contain a complementary determining region (CDR region). The proteins and protein fragments may be antibodies, and the terms "antibody" and "full-length antibody" include polyclonal antibodies and monoclonal antibodies. In addition, the term "antibody" includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, chimeric, bifunctional and humanized antibodies, and related synthetic isoforms. Non-naturally occurring antibodies are also referred to herein as "recombinant antibodies," and the term "antibody" can be used interchangeably with "immunoglobulin."

[0013] Proteins and protein fragments can also be antigen-binding fragments that contain part or all of the antibody CDRs, which lack at least some of the amino acids present in the full-length chain but are still able to specifically bind to the antigen. Such fragments are biologically active because they bind to the target antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments are selected from, but not limited to, F(ab')2, Fab', Fab, Fv (composed of VH and VL), ScFv (single-chain antibody, VH and VL are connected by a connecting peptide), dsFv (disulfide stabilized Fv fragments, dsFv), bispecific antibodies, nanobodies, and any one of the minimum recognition units of antibodies. In addition to the above functional fragments, any fragments with increased half-life are also included.

[0014] The "variable region" or "variable domain" of a binding protein refers to the domain of the amino terminus of the heavy chain or light chain of an antibody that recognizes and binds to an antigen. The composition and arrangement of the amino acids in this segment determine the specificity of the antibody in recognizing the antigen. The heavy chain variable domain may be referred to as "VH". The variable domain of the light chain may be referred to as "VL". These domains are usually the most variable parts of an antibody and contain antigen binding sites. The variable regions of the heavy and light chains are each composed of three complementarity-determining regions (CDR) (also known as hypervariable regions) connected by four framework regions (FR). The extent of the framework region and CDR has been precisely defined, for example, in Kabat (see Sequences of Proteins of Immunological Interest, E. Kabat et al.) and Chothia. Any CDR determination method well known in the art, including a combination of methods, can identify the CDRs of the variable domain. The CDRs in each chain are held together closely by FRs to form the variable region. Generally, the variable regions VL / VH of the heavy and light chains can be obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0015] The term "constant region" or "constant domain" of an antibody refers to the constant region of an antibody light chain or the constant region of an antibody heavy chain, either alone or in combination. The heavy chain of an antibody has one variable domain (VH), followed by a number of constant domains or regions, such as one or more of a hinge, CH1, CH2, CH3, and CH4, the CH1 domain being adjacent to the VH domain and at the amino terminus of the hinge region of the antibody heavy chain, and not forming part of the Fc region of the antibody; the hinge region includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain; the N-terminus of CH2 is usually the CH3 domain, which usually forms the C-terminal portion of the antibody, and in some antibody types, such as IgM and IgE, the constant region also includes a CH4 domain. The constant region of an antibody can be derived from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, as well as subclasses and mutant forms of the constant regions thereof.

[0016] The present invention does not limit the method of obtaining PCNA binding protein. In some optional embodiments, the polynucleotide encoding PCNA binding protein is connected to a vector and then expressed in a cell to obtain the corresponding antibody. The above-mentioned vector can be introduced into eukaryotic cells, especially mammalian cells, to construct and obtain the PCNA binding protein that can be expressed. In other optional embodiments, the binding protein can also be obtained by recombinant genetics techniques known to those skilled in the art or by peptide synthesis, such as automatic peptide synthesizers (such as automatic peptide synthesizers sold by Applied BioSystems, etc.); the antigen binding fragment can also be optionally produced by enzymatic cleavage of antigen binding molecules (including complete antibodies), such as pepsin or papain cleavage; or chemical cleavage, such as obtaining the above-mentioned antigen binding fragment by chemical reduction splitting disulfide bonds.

[0017] The terms "specific recognition", "selective binding", "selectively binds" and "specifically binds" or similar expressions refer to the binding of a binding protein to an epitope on a predetermined antigen. Typically, the binding protein is present at a rate of less than about 10 -5 M, for example, less than about 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or smaller K d The K value of an antibody can be determined using methods well established in the art. d Other standard assays for evaluating the binding ability of a ligand, such as an antibody, to a target are known in the art and include, for example, ELISA, Western blot, RIA, and flow cytometry analysis.

[0018] The term "polynucleotide" herein refers to the polymer form of nucleotides of any length, and polynucleotides include ribonucleotides and / or deoxyribonucleotides. Examples of polynucleotides include but are not limited to single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids or polymers comprising purine and pyrimidine bases or other natural, chemical or biochemically modified, non-natural or derived nucleotide bases. Polynucleotide encoding the above-mentioned PCNA binding protein, encoding is alternatively encoding sense strand or antisense strand. Polynucleotides can be naturally occurring, synthetic, recombinant or any combination thereof. The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.

[0019] The term "vector" as used herein refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express a protein encoded by the inserted polynucleotide, the vector is called an expression vector. A vector can be introduced into a cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the cell.

[0020] The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as lambda phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).

[0021] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Progeny may not necessarily be identical to the original cell due to natural, accidental or deliberate mutation, and may differ from the original cell in morphology and / or in genomic DNA. "Transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom.

[0022] As used herein, the term "purified" or "isolated" in connection with a polypeptide or nucleic acid means that the polypeptide or nucleic acid is not in its natural medium or natural form. Thus, the term "isolated" includes a polypeptide or nucleic acid removed from its original environment, such as if it is naturally present, from its natural environment. For example, an isolated polypeptide is generally free of at least some proteins or other cellular components that are normally associated with it or are normally mixed with it or in solution. Isolated polypeptides include naturally produced polypeptides contained in cell lysates, polypeptides in purified or partially purified form, recombinant polypeptides, polypeptides expressed or secreted by cells, and polypeptides in heterologous cells or cultures. In connection with nucleic acids, the term isolated or purified indicates, for example, that the nucleic acid is not in its natural genomic context (e.g., in a vector, as an expression cassette, connected to a promoter, or artificially introduced into a heterologous cell).

[0023] Herein, "PCNA antibody-positive disease" refers to a disease that can cause the patient's PCNA antibodies to be higher than the level when the patient does not have the disease. Exemplary PCNA antibody-positive diseases include, but are not limited to, autoimmune diseases (e.g., lupus erythematosus), viral infections (e.g., chronic hepatitis B virus infection or hepatitis C virus infection), or cancer (e.g., small cell lung cancer).

[0024] In a first aspect, a PCNA binding protein is provided, which comprises a heavy chain variable region and a light chain variable region.

[0025] The heavy chain variable region includes complementary determining regions VH-CDR1, VH-CDR2 and VH-CDR3; the light chain variable region includes complementary determining regions VL-CDR1, VL-CDR2 and VL-CDR3;

[0026] The VH-CDR1, VH-CDR2 and VH-CDR3 include amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; the VL-CDR1, VL-CDR2 and VL-CDR3 include amino acid sequences consistent with VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQID NO.2.

[0027] It is understood that the amino acid sequences of other regions except the CDR region in the variable region shown in SEQ ID NO.1 or 2 are not used to limit the PCNA-binding protein provided by the present invention. For example, if the PCNA-binding protein provided by the present application contains a framework region, it may be different from the framework region in the variable region shown in SEQ ID NO.1 or 2. The CDR region in the variable region shown in SEQ ID NO.1 or 2 can be divided according to an optional method known in the art. Optionally, the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3 of the variable region are defined by any one of the systems of Kabat, Chothia, IMGT, ABM or Contact or a combination of multiple definition systems. Taking the Kabat, Chothia, IMGT, ABM or Contact definitions as examples, the amino acid sequences of VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1 and the amino acid sequences of VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.2 are shown in Table 1:

[0028] Table 1

[0029]

[0030]

[0031] In an optional embodiment, the PCNA binding protein has VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region defined in Table 1, and VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region defined in Table 1. Taking the IMGT definition as an example: the amino acid sequence of the VH-CDR1 is shown in SEQ ID NO.11, the amino acid sequence of the VH-CDR2 is shown in SEQ ID NO.16, and the amino acid sequence of the VH-CDR3 is shown in SEQ ID NO.19; the amino acid sequence of the VL-CDR1 is shown in SEQ ID NO.22, the amino acid sequence of the VL-CDR2 is ATS, and the amino acid sequence of the VL-CDR3 is shown in SEQ ID NO.25.

[0032] In an optional embodiment, the heavy chain variable region further comprises a framework region, and / or the light chain variable region further comprises a framework region. The species origin of the framework region includes, but is not limited to, one or more of rabbit, cattle, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, camel, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock, human and their mutants.

[0033] In an optional embodiment, the amino acid sequence of the heavy chain variable region of the PCNA binding protein is shown as SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO.2.

[0034] In an alternative embodiment, the PCNA binding protein is an antibody or antigen binding fragment comprising a constant region.

[0035] In an alternative embodiment, at least a portion of the constant region sequence of the PCNA binding protein is a human constant region sequence.

[0036] In an optional embodiment, the constant region sequence of the PCNA-binding protein is selected from the sequence of part or all of the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD, and the IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD include their subclasses and mutant forms.

[0037] In an alternative embodiment, the PCNA binding protein contains a heavy chain constant region.

[0038] In an optional embodiment, the heavy chain constant region sequence of the PCNA binding protein is selected from a portion or all of the constant region sequence of human IgG1, preferably including CH1, CH2 and CH3 of the constant region of human IgG1.

[0039] In an optional embodiment, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3.

[0040] In an optional embodiment, the PCNA binding protein contains a light chain constant region.

[0041] In an optional embodiment, the light chain constant region sequence is selected from the light chain constant region of a mouse.

[0042] In an optional embodiment, the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4.

[0043] In an optional embodiment, the PCNA binding protein is a human-mouse chimeric antibody, the heavy chain amino acid sequence of the PCNA binding protein is shown in SEQ ID NO.5, and the light chain amino acid sequence is shown in SEQ ID NO.6.

[0044] In the second aspect, a biological material is also provided, including a polynucleotide, a vector or a cell; wherein the polynucleotide encodes the above-mentioned PCNA binding protein; the vector carries the polynucleotide; the cell carries the polynucleotide, or contains the vector or is capable of expressing the PCNA binding protein.

[0045] After the polynucleotide encoding the PCNA binding protein is connected to the vector, the vector can be introduced into eukaryotic cells, especially mammalian cells, to construct a cell line capable of expressing the PCNA binding protein, and the corresponding protein can be obtained by cell expression.

[0046] In an optional embodiment, the cells used to express PCNA binding protein are 293 cells (human kidney epithelial cell line), preferably 293F cells.

[0047] In an optional embodiment, the cells used to express PCNA binding protein are CHO cells (Chinese Hamster Ovary cells).

[0048] In a third aspect, a method for preparing the PCNA binding protein of the first aspect is also provided, comprising culturing cells capable of expressing the PCNA binding protein.

[0049] In an optional embodiment, the preparation method further comprises transforming the polynucleotide encoding the PCNA binding protein into cells and expressing the polynucleotide, and obtaining the PCNA binding protein by purification.

[0050] In an optional embodiment, the preparation method further comprises synthesizing a polynucleotide containing the PCNA binding protein encoding gene as required, and / or preparing a suitable expression vector as required, transforming the expression vector into a desired cell and expressing it, and obtaining the PCNA binding protein by purification.

[0051] In an optional embodiment, the cell is obtained by transforming a polynucleotide encoding a PCNA-binding protein as described in the first aspect into a cell, wherein the polynucleotide comprises a heavy chain expression plasmid and a light chain expression plasmid, and the transformation comprises co-transforming the heavy chain expression plasmid and the light chain expression plasmid into the cell.

[0052] In an optional embodiment, the constant region fragment is fused to the C-terminus of the heavy chain variable region to construct a complete heavy chain expression plasmid.

[0053] In an optional embodiment, the constant region fragment includes one or more of CH1, CH2 and CH3, preferably includes CH1, CH2 and CH3.

[0054] In an optional embodiment, the cell is a eukaryotic cell, preferably a mammalian cell.

[0055] In an optional embodiment, the mammalian cells include 293 cells or CHO cells, preferably 293F cells.

[0056] In a fourth aspect, there is also provided the use of the PCNA binding protein of the first aspect or the biomaterial of the second aspect in any one of the following (I) to (VII):

[0057] (I) PCNA antibody testing for non-diagnostic and therapeutic purposes;

[0058] (II) preparing products for detecting PCNA antibodies;

[0059] (III) Preparation of products for diagnosing PCNA antibody-positive diseases;

[0060] (IV) PCNA detection for non-diagnostic and therapeutic purposes;

[0061] (VII) preparing products for detecting PCNA;

[0062] (VI) used for purification of PCNA;

[0063] (VII) preparing a product for purifying PCNA;

[0064] For detecting PCNA antibodies or in diagnosing PCNA antibody-positive diseases, PCNA binding protein can be used as a standard and / or quality control product during detection to provide a reliable reference for the test results, and can also be used to construct a standard curve.

[0065] In an optional embodiment, the product for preparing a diagnosis of a PCNA antibody-positive disease includes a product for preparing a diagnosis or auxiliary diagnosis of an autoimmune disease. The PCNA antibody-positive disease includes preparing a diagnosis or auxiliary diagnosis of an autoimmune disease, a viral infection, or a cancer. The autoimmune disease optionally includes systemic lupus erythematosus; the viral infection optionally includes chronic hepatitis B virus infection or hepatitis C virus infection; the cancer optionally includes small cell lung cancer.

[0066] The application of the above aspect (IV) can utilize the PCNA binding protein to specifically target and bind to PCNA, and realize the detection of PCNA or cells expressing PCNA based on immunodetection technology. For example, when the PCNA binding protein is an immunoconjugate, for example, it is connected with a fluorescent group, and a fluorescence detection device can be used to realize the positioning or real-time detection of PCNA. For example, it can be used for immunoblotting, immunoprecipitation or flow cytometry, etc., which involve the use of the specific binding properties of PCNA antigen and antibody to detect PCNA. Based on the PCNA binding protein's ability to specifically target and bind to PCNA, it can also be used for the purification of PCNA in aspect (VI).

[0067] In an optional embodiment, in the above aspects (II), (III), (V) or (VII), those skilled in the art can prepare corresponding products (such as the above-mentioned immunoconjugates) according to actual uses, and select other reagents in the product, including but not limited to one or more of tracer markers, solid phase carriers, buffer reagents, salts, secondary antibodies, chromogenic substrates, blocking solutions, washing solutions, solvents, eluents, coupling agents, negative controls, positive controls, standards, quality control products and markers.

[0068] In a fifth aspect, a reagent or a kit is also provided, wherein the reagent or the kit comprises the PCNA binding protein of the first aspect or the biological material of the second aspect.

[0069] In an optional embodiment, the kit is used to detect PCNA antibodies or PCNA antibody-positive diseases; the autoantibody-positive diseases include but are not limited to idiopathic inflammatory myopathy, anti-synthetase syndrome, myositis, lupus erythematosus, Sjögren's syndrome, neonatal lupus erythematosus, primary biliary cholangitis, idiopathic inflammatory myopathy and one or more of rheumatoid arthritis and other autoimmune diseases. The kit includes standard substances and / or quality control substances, and the standard substances and / or quality control substances contain the PCNA-binding protein.

[0070] In an optional embodiment, the kit further comprises a detection reagent, and the detection reagent comprises a PCNA antibody detection reagent.

[0071] In an optional embodiment, the kit further comprises a detection reagent for an antibody of at least one of the following substances: at least one of dsDNA, nucleosome, histone, Sm, ribosomal P protein, Scl-70, SS-A-52, SS-A-60, CENP-B, AMA M2, ssb, Jo-1, PM-Scl, Mi-2, Ku and RNP / sm.

[0072] In an optional embodiment, the kit further comprises a solid phase carrier.

[0073] In an optional embodiment, the PCNA-binding protein in the reagent or kit is coupled to a solid phase carrier; or the PCNA-binding protein in the reagent or kit is packaged independently with the solid phase carrier. By coupling the PCNA-binding protein to a solid phase carrier, it can be used to capture the PCNA protein in the sample to be tested. Or by coupling the PCNA-binding protein to a solid phase carrier, it can be used to purify the PCNA protein.

[0074] In an optional embodiment, the PCNA antibody detection reagent includes a solid phase carrier coupled to a PCNA antigen.

[0075] In an optional embodiment, the kit further comprises a tracing marker.

[0076] In an optional embodiment, the PCNA binding protein in the reagent or the kit is coupled with a tracer marker; or the PCNA binding protein in the reagent or the kit and the tracer marker are packaged separately. By coupling the PCNA binding protein with the tracer marker, it can be used to locate and detect PCNA protein or detect PCNA protein in a sample by Western blotting.

[0077] The above reagents or kits may also optionally include reagents and / or consumables used in the art for detection reactions or protein purification, which are well known to those skilled in the art, including but not limited to one or more of buffer reagents, salts, secondary antibodies, chromogenic substrates, blocking solutions, washing solutions, solvents, eluents, coupling agents, negative controls, positive controls, standards, quality control products and markers.

[0078] The above reagents or kits can be used in general immunoassay methods acceptable in the art, including but not limited to immunofluorescence staining, flow sorting, immunoblotting, immunohistochemistry, ELISA, immunochromatography or immunomagnetic beads. Those skilled in the art can prepare reagents or other reagents in the kit according to the corresponding detection means, and the present invention is not limited to this.

[0079] The tracer markers in any of the above embodiments include, but are not limited to, one or more of enzymes, luminescent markers, fluorescent microspheres, colored microspheres, latex microspheres, colloidal gold, quantum dots, biotin, streptavidin, radionuclides, radiocontrast agents, paramagnetic ions, metals, and photosensitizers.

[0080] Examples of enzymes include, but are not limited to, alkaline phosphatase or horseradish peroxidase. Examples of luminescent markers include, but are not limited to, fluorescent proteins, synthetic small molecules or polymer dyes, and specific examples include, but are not limited to, Alexa350, Alexa 405, Alexa430, Alexa 488, Alexa 555, Alexa 647, AMCA, aminoacridine, BODIPY630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 5-carboxy-2′,4′,5′,7′-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethylrhodamine, Cascade Blue, Cy2, Cy3, Cy5, Cy7, 6-FAM, dansyl chloride, fluorescein, HEX, 6-JOE, NBD (7-nitrobenzo-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green514, Pacific Blue, phthalic acid, terephthalic acid, isophthalic acid, cresol fast violet, cresol blue violet, brilliant cresol blue, p-aminobenzoic acid, erythrosine, phthalocyanine, azomethine, cyanine, xanthine, succinylfluorescein, rare earth metal cryptates, trisbipyridyl diamine europium, europium cryptates or chelates, diamines, bicyanines, La Jolla blue dye, allophycocyanin, allococyanin One or more of B, phycocyanin C, phycocyanin R, thiamine, phycoerythrin, phycoerythrin R, REG, rhodamine green, rhodamine isothiocyanate, rhodamine red, ROX, TAMRA, TET, TRIT (tetramethylrhodamine isothiol), tetramethylrhodamine and Texas Red. Fluorescent microspheres, colored microspheres and latex microspheres are independently selected from products acceptable in the art, such as commercially available products. Radionuclides include but are not limited to 110 In, 111 In, 177 Lu, 18 F. 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga,68 Ga, 86 Y. 90 Y. 89 Zr, 94 mTc, 94 Tc, 99 mTc, 120 I. 123 I. 124 I. 125 I. 131 I. 154-158 Gd, 32 P. 11 C. 13 N. 15 O. 186 Re, 188 Re, 51 Mn, 52 mMn, 55 Co. 72 As, 75 Br, 76 Br, 82 mRb and 83 Paramagnetic ions include, but are not limited to, one or more of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (III).

[0081] The solid phase carrier in any of the above embodiments includes but is not limited to microtubes, columns, microparticles, nitrocellulose membranes, chromatography matrices or lateral flow devices; more specifically, for example, but not limited to, enzyme-labeled wells, immunochromatographic test strips or magnetic beads. The chromatography matrix can be any known chromatography matrix acceptable in the art, including but not limited to polystyrene, polysaccharide polymers or silica gel. In an optional embodiment, the chromatography matrix includes gel particles.

[0082] The present invention discloses a PCNA binding protein that specifically recognizes and binds to PCNA antigen, and further prepares a human-mouse chimeric recombinant monoclonal antibody. The present invention has the following beneficial effects:

[0083] (1) The sequence of the PCNA binding protein prepared by this method is known and can be recombinantly expressed in vitro. The operation is simple, time-saving, and the production process is controllable, the product batch difference is small, and the stability is good. It has good application prospects.

[0084] (2) The PCNA binding protein can be coupled to a chromatography matrix for immunoaffinity chromatography purification of PCNA antigen to improve protein purity. The PCNA binding protein can also be coupled to a marker for detection of PCNA antigen, including but not limited to the use of liquid phase chips, immunofluorescence staining, flow sorting, fluorescent microspheres and other technologies to identify PCNA antigen.

[0085] (3) As a quality control product in the detection kit, it can alleviate the problems of complicated operation of immune polyclonal antibodies and low subsequent coupling efficiency, reduce production costs, stabilize product quality, and significantly improve the reaction value; on the other hand, compared with the direct use of human serum, it can also avoid the problem of difficult sample sources and high costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0087] Figure 1 The SDS-PAGE protein electrophoresis diagram of the anti-PCNA recombinant monoclonal antibody in Example 1, M represents Maeker, reduced represents the reduced SDS-PAGE electrophoresis result of the PCNA recombinant antibody, the heavy chain and light chain are 50kDa and 25kDa respectively, and non-reduced represents the non-reduced SDS-PAGE electrophoresis result of the PCNA recombinant antibody, the size is about 150kDa;

[0088] Figure 2 The ELISA analysis results of the binding between the recombinant monoclonal antibody and the PCNA protein in Example 2, Ab-PCNA is the binding activity of the recombinant monoclonal antibody to the PCNA antigen, and Ab-BSA is the non-specific binding activity of the recombinant monoclonal antibody to the control protein BSA. DETAILED DESCRIPTION

[0089] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0090] Example 1 Preparation of PCNA chimeric antibody

[0091] A PCNA-specific high-affinity monoclonal strain was screened using phage display technology, and the Fab region sequence was obtained after sequencing. The heavy chain variable region is shown in SEQ ID NO.1, the light chain variable region is shown in SEQ ID NO.2, and the CDR region is shown in Table 1.

[0092] Heavy chain variable region (SEQ ID NO.1)

[0093] EVKIEESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYIYPGSGGSYNPSL KSRISITRDTSKNQFFLQLNSVTAEDTATYYCTRANYGNYFDYWGQGTTLTVSS.

[0094] Light chain variable region (SEQ ID NO.2)

[0095] DVQMNQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQEPDGTIKRLIYATSSLDSGVPKRFSGS RSGSDYSLTISSLESEDFVDYYCLQYASSPRTFGGGTKLEIK.

[0096] Table 1

[0097]

[0098] The complete light chain gene and heavy chain gene were synthesized and inserted into the vector PTT5 respectively, and the competent cells were transformed and cultured to obtain the corresponding expression plasmids. Among them, the light chain constant region sequence is shown in SEQ ID NO.4, which is a mouse sequence; the light chain complete sequence is shown in SEQ ID NO.6. The heavy chain constant region sequence is shown in SEQ ID NO.3, which is a human sequence, and the heavy chain complete sequence is shown in SEQ ID NO.5.

[0099] The heavy chain expression plasmid and the light chain expression plasmid were mixed with PEI at a molar ratio of 1:2 and transfected into 293F suspension cells in the logarithmic growth phase. The cells were cultured in a shaking incubator at 37°C and 120 rpm. After 5 days, the cell supernatant was collected, the antibody was purified with Protein A, eluted with 0.1M Glycine (pH3.0), and neutralized with 1M Tris (PH8.0). After elution, the ultrafiltration centrifuge tube was replaced with PBS buffer and concentrated, and the protein concentration was determined. The obtained product was verified by SDS-PAGE, and the results are as follows: Figure 1 shown.

[0100] Example 2 ELISA determination of the binding activity of recombinant monoclonal antibodies to PCNA antigen

[0101] (1) PCNA protein (2 μg / mL) was coated on an ELISA plate, and BSA was also coated as a nonspecific binding control and incubated at 4°C overnight.

[0102] (2) Discard the coating solution, wash the plate three times with PBST, pat dry, add 3% milk, and block at 37°C for 2 h.

[0103] (3) The blocking solution was discarded, the plate was washed 3 times with PBST, patted dry, and the antibody prepared in Example 1 was added (multiple concentration gradient experimental groups were set up, starting at 1 μM, and 3-fold gradient dilution), and incubated at 37° C. for 1.5 h.

[0104] (4) Discard the primary antibody, wash the plate 5 times with PBST, pat dry, add horseradish peroxidase (HRP)-labeled mouse anti-human IgG secondary antibody, and incubate at 37°C for 1 h.

[0105] (5) Discard the secondary antibody, wash the plate 5 times with PBST, pat dry, add the colorimetric substrate for color development, add the stop solution after 15 min to stop the reaction, and measure the OD value with an enzyme reader.

[0106] (6) A nonlinear fitting plot was performed with the OD value as the ordinate and the logarithm of the antibody molar concentration as the abscissa.

[0107] The results are as follows Figure 2 As shown, the EC50 value of the antibody was approximately 4.94 nM.

[0108] Example 3 Stability of anti-PCNA recombinant monoclonal antibody

[0109] A control antibody was prepared by the method of reference Example 1: VH-CDR1, VH-CDR2 and VH-CDR3 in the heavy chain variable region shown in SEQ ID NO.1 in Example 1 and VL-CDR1, VL-CDR2 and VL-CDR3 in the light chain variable region shown in SEQ ID NO.2 were replaced with corresponding CDRs (HCDR1: VYAFSSSW, HCDR2: IYPADGDT, HCDR3: ARWLRAMDY; LCDR1: QNVGTN, LCDR2: SAS, LCDR3: QQYNSYPYT) in CN110300761B (application number CN201780086509.4, invention name anti-PCNA monoclonal antibody and use thereof) to obtain a control antibody, which differs from the antibody prepared in Example 1 only in the CDR region.

[0110] The PCNA humanized antibody and control antibody in Example 1 were diluted to 2 mg / mL, and then diluted 2000 times with this concentration as the initial concentration. After being placed at -80°C, 4°C and 37°C for 7 days, they were tested by the fully automatic multiple immunoassay analyzer of Zhuhai Livzon Reagent Co., Ltd.

[0111] The detection process is as follows:

[0112] Step 1: The fully automatic multiplex immunoassay analyzer draws 20 μL of the sample and automatically dilutes it 15 times.

[0113] Step 2: Take 15 μL of the diluted sample, add 100 μL of PCNA antigen-coupled magnetic barcode, incubate at 37°C for 15 min, perform magnetic separation after incubation, and wash 3 times.

[0114] Step 3: Add 50 μL of phycoerythrin-labeled mouse anti-human IgG antibody, incubate at 37°C for 15 min, perform magnetic separation after incubation, and wash three times.

[0115] Step 4: The instrument automatically identifies each magnetic barcode and detects the fluorescence intensity of the corresponding complex, and then automatically converts it into an antibody index. The test results are shown in Table 2.

[0116] Table 2

[0117]

[0118] In Table 2, PCNA-Ab01 is the antibody prepared in Example 1, and PCNA-Ab02 is the control antibody.

[0119] It can be seen from Table 2 that after the antibody prepared in Example 1 was diluted 2000 times and treated at 4°C for 7 days, the signal retention rate was 100%. The control antibody decreased by 14%. After being treated at 37°C for 7 days, the signal retention rate of the antibody prepared in Example 1 was close to 93%. The control antibody decreased by 31%. In summary, the stability of the antibody prepared in the present invention is significantly better than that of the control antibody.

[0120] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. PCNA binding protein, It is characterized in that comprising a heavy chain variable region and a light chain variable region; The heavy chain variable region includes complementary determining regions VH-CDR1, VH-CDR2 and VH-CDR3; the light chain variable region includes complementary determining regions VL-CDR1, VL-CDR2 and VL-CDR3; The VH-CDR1, VH-CDR2 and VH-CDR3 include amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; the VL-CDR1, VL-CDR2 and VL-CDR3 include amino acid sequences consistent with VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.

2.

2. PCNA-binding protein according to claim 1, It is characterized in that The VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3 of the variable region are defined by any one of the Kabat, Chothia, IMGT, ABM or Contact systems or a combination of multiple definition systems; Optionally, according to the IMGT definition: the amino acid sequence of the VH-CDR1 is shown as SEQ ID NO.11, the amino acid sequence of the VH-CDR2 is shown as SEQ ID NO.16, and the amino acid sequence of the VH-CDR3 is shown as SEQ ID NO.19; the amino acid sequence of the VL-CDR1 is shown as SEQ ID NO.22, the amino acid sequence of the VL-CDR2 is ATS, and the amino acid sequence of the VL-CDR3 is shown as SEQ ID NO.

25.

3. PCNA-binding protein according to claim 1, It is characterized in that The heavy chain variable region further comprises a framework region, and / or the light chain variable region further comprises a framework region; Optionally, the amino acid sequence of the heavy chain variable region of the PCNA binding protein is shown as SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO.

2.

4. The PCNA binding protein according to any one of claims 1 to 3, It is characterized in that The PCNA binding protein is a complete antibody, F(ab') 2 , Fab', Fab, Fv, scFv, dsFv, bispecific antibody and one of the minimum recognition units of antibodies; Optionally, the species from which the remaining sequence of the antibody originates include one or more of mice, rats, guinea pigs, hamsters, rabbits, ferrets, cats, dogs, goats, sheep, cows, pigs, horses, monkeys and humans.

5. The PCNA binding protein according to any one of claims 1 to 3, It is characterized in that It also contains a constant region; Optionally, at least a portion of the constant region sequence is a human constant region sequence; Optionally, the constant region sequence is selected from a sequence of a partial or complete constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Optionally, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3; Optionally, the PCNA-binding protein contains a light chain constant region, and the light chain constant region sequence is selected from a mouse light chain constant region; Optionally, the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4; Optionally, the heavy chain amino acid sequence of the PCNA binding protein is shown as SEQ ID NO.5, and the light chain amino acid sequence is shown as SEQ ID NO.

6.

6. Biomaterials, It is characterized in that including a polynucleotide, a vector or a cell; The polynucleotide encodes the PCNA binding protein according to any one of claims 1 to 5; The vector carries the polynucleotide; The cell carries the polynucleotide, or contains the vector, or is capable of expressing the PCNA binding protein according to any one of claims 1 to 5.

7. A method for preparing a PCNA binding protein according to any one of claims 1 to 5, It is characterized in that Comprising culturing the cell as claimed in claim 6; Optionally, the cell is obtained by transforming a polynucleotide encoding a PCNA binding protein as described in any one of claims 1 to 5 into a cell, wherein the polynucleotide comprises a heavy chain expression plasmid and a light chain expression plasmid, and the transformation comprises co-transforming the heavy chain expression plasmid and the light chain expression plasmid into the cell; Optionally, the cell is a eukaryotic cell, preferably a mammalian cell; Optionally, the mammalian cells include 293 cells or CHO cells, preferably 293F cells.

8. Use of the PCNA binding protein according to any one of claims 1 to 5, or the biomaterial according to claim 6 in any one of the following (I) to (VII): (I) PCNA antibody testing for non-diagnostic and therapeutic purposes; (II) preparing products for detecting PCNA antibodies; (III) Preparation of products for diagnosing PCNA antibody-positive diseases; (IV) PCNA detection for non-diagnostic and therapeutic purposes; (V) preparing products for detecting PCNA; (VI) used for purification of PCNA; (VII) preparing a product for purifying PCNA; Optionally, the preparation of products for diagnosing PCNA antibody-positive diseases includes preparing products for diagnosing or assisting in the diagnosis of autoimmune diseases, viral infections or cancers; Optionally, the autoimmune disease comprises systemic lupus erythematosus; Optionally, the viral infection comprises chronic hepatitis B virus infection or hepatitis C virus infection; Optionally, the cancer comprises small cell lung cancer; Optionally, the PCNA binding protein is used as a standard or quality control product.

9. Reagents or kits, It is characterized in that The reagent or kit comprises the PCNA binding protein according to any one of claims 1 to 5, or the biological material according to claim 6.

10. The reagent or kit according to claim 9, It is characterized in that The kit is used for detecting PCNA antibodies or for detecting PCNA antibody-positive diseases; the kit comprises a standard substance and / or a quality control substance, and the standard substance and / or the quality control substance contain the PCNA binding protein; Optionally, the kit further comprises a PCNA antibody detection reagent; Optionally, the kit further comprises a detection reagent of an antibody of at least one of the following substances: at least one of dsDNA, nucleosome, histone, Sm, ribosomal P protein, Scl-70, SS-A-52, SS-A-60, CENP-B, AMA M2, ssb, Jo-1, PM-Scl, Mi-2, Ku and RNP / sm.

Citation Information

Patent Citations

  • Use of PCNA autoantibody in cancer prediction, diagnosis and prognosis evaluation

    CN113030457A

  • Coding gene of heavy / light chain variable region of anti-PCNA recombinant antibody as well as recombinant antibody and application thereof

    CN116496393A

  • SSA / Ro52 binding protein, preparation method and application

    CN118240089A

Cited By

  • Anti-LC-1 antibody or antigen binding fragment thereof, preparation method and application

    CN119504992A

  • BCOADC binding protein, preparation method and application thereof

    CN119552255A

  • Binding protein specifically binding to mycoplasma pneumoniae P1 protein, and preparation method and application thereof

    CN119661704A

  • Monoclonal antibody against p21 protein, antibody conjugate and application thereof

    CN119684449A

  • Anti-p21 protein monoclonal antibody, antibody conjugate and its application

    CN119684449B